Euro RSCG Life splits PR function, recruits Catlett

Share this article:
Euro RSCG Life has split its communications practice into product and corporate PR divisions, naming former Ketchum healthcare head David Catlett president of the product PR unit.

Catlett will serve as president of Euro RSCG Life PR, which will handle product PR for clients including Sanofi-Aventis, Galderma and Colgate-Palmolive's Hill's Pet Nutrition. Noonan Russo, formerly the firm's healthcare PR brand, will handle investor relations and other corporate PR functions, with a focus on biotechs, and continues to be led by Tony Russo.

After starting out in pharmaceuticals with Novartis predecessor Ciba-Geigy, Searle, Abbott and the Chicago Lung Association, Catlett spent 15 years at Ketchum, building its global healthcare practice and handling major brands like Lipitor. He and Russo report to Al Paz, CEO of Havas network's marketing services group.

Euro RSCG Life PR is “a little smaller and more focused” than Ketchum, Catlett said, adding that the network's exclusive focus on healthcare gives the firm a boutique feel. “There's also a lot of resources that can be brought to bear to service our clients.” Client brands include Sanofi-Aventis' Lantus and Lovenox and Galderma's Differin, Tri-Luma and MetroGel.

Catlett's successor has not yet been appointed, but Nancy Hicks has become associate director of the North American healthcare practice, a new position. Hicks was previously head of the firm's Washington practice. Ketchum's global healthcare practice reports to Lorraine Thelian, senior partner.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union